BAVA Bavarian Nordic A/S

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, November 11, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NamePaul Chaplin
2.Reason for the notification
a)Position/status



 
President and Chief Executive Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.00123,645
d)Aggregated information
  • Aggregated volume
  • Price
 



123,645

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameHenrik Juuel
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Financial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0056,210
d)Aggregated information
  • Aggregated volume
  • Price
 



56,210

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameHenrik Birk
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0052,617
d)Aggregated information
  • Aggregated volume
  • Price
 



52,617

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameTommi Kainu
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Business Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0051,157
d)Aggregated information
  • Aggregated volume
  • Price
 



51,157

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameJean-Christophe May
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Commercial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0047,970
d)Aggregated information
  • Aggregated volume
  • Price
 



47,970

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameLaurence De Moerlooze
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Medical Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0047,965
d)Aggregated information
  • Aggregated volume
  • Price
 



47,965

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameAnu Helena Kerns
2.Reason for the notification
a)Position/status



 
Executive Vice President People & Organization of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0036,476
d)Aggregated information
  • Aggregated volume
  • Price
 



36,476

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit .

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 48 / 2020

Attachment

EN
11/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Offentliggørelse af redegørelse af bestyrelsen vedrørende overtagelses...

Offentliggørelse af redegørelse af bestyrelsen vedrørende overtagelsestilbud til aktionærerne i Bavarian Nordic fra konsortium ledet af Nordic Capital og Permira MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, August 26, 2025 – Med henvisning til selskabsmeddelelsen af 26. august 2025 (nr. 24/2025) angående offentliggørelsen af tilbudsdokumentet vedrørende det frivillige offentlige overtagelsestilbud ...

 PRESS RELEASE

Publication of statement by the Board of Directors in respect of the t...

Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, August 26, 2025 – With reference to Bavarian Nordic A/S' ("Bavarian Nordic" or the "Company") announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document concerning th...

 PRESS RELEASE

Offentliggørelse af tilbudsdokument vedrørende overtagelsestilbud til ...

Offentliggørelse af tilbudsdokument vedrørende overtagelsestilbud til aktionærerne i Bavarian Nordic fra konsortium ledet af Nordic Capital og Permira og nedsættelse af minimumsbetingelsen for accept til 75% MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, August 26, 2025 – Med henvisning til selskabsmeddelelsen af 28. juli 2025 (nr. 21/2025) vedrørende indgåelsen af en bindende aftale mellem Innosera ...

 PRESS RELEASE

Publication of offer document in respect of the takeover offer to the ...

Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75% NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, August 26, 2025 – With reference to the announcement of 28 July 2025 (no. 21/2025) regarding the entering into of a binding agreement between Innosera ApS (the "Offeror")...

 PRESS RELEASE

Bavarian Nordic offentliggør regnskab for første halvår 2025

Bavarian Nordic offentliggør regnskab for første halvår 2025 KØBENHAVN, Danmark, 22. august 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag regnskab samt rapporterede på begivenheder for første halvår 2025. Desuden offentliggør selskabet finanskalender for 2026. Omsætningen i første halvår steg med 33% til DKK 2.998 mio., hvilket afspejler en stærk udvikling i både Travel Health og Public Preparedness. Travel Health omsætning steg med 24% til DKK 1.386 mio. sammenlignet med første halvår 2024, hvilket primært var drevet af øget efterspørgsel på vacciner mod rabies og flåtbår...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch